These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 33885179)

  • 1. Gut-restricted apical sodium-dependent bile acid transporter inhibitor attenuates alcohol-induced liver steatosis and injury in mice.
    Matye DJ; Li Y; Chen C; Chao X; Wang H; Ni H; Ding WX; Li T
    Alcohol Clin Exp Res; 2021 Jun; 45(6):1188-1199. PubMed ID: 33885179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a highly potent, nonabsorbable apical sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of type 2 diabetes.
    Wu Y; Aquino CJ; Cowan DJ; Anderson DL; Ambroso JL; Bishop MJ; Boros EE; Chen L; Cunningham A; Dobbins RL; Feldman PL; Harston LT; Kaldor IW; Klein R; Liang X; McIntyre MS; Merrill CL; Patterson KM; Prescott JS; Ray JS; Roller SG; Yao X; Young A; Yuen J; Collins JL
    J Med Chem; 2013 Jun; 56(12):5094-114. PubMed ID: 23678871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined ASBT Inhibitor and FGF15 Treatment Improves Therapeutic Efficacy in Experimental Nonalcoholic Steatohepatitis.
    Matye DJ; Wang H; Luo W; Sharp RR; Chen C; Gu L; Jones KL; Ding WX; Friedman JE; Li T
    Cell Mol Gastroenterol Hepatol; 2021; 12(3):1001-1019. PubMed ID: 33965587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.
    Baghdasaryan A; Fuchs CD; Österreicher CH; Lemberger UJ; Halilbasic E; Påhlman I; Graffner H; Krones E; Fickert P; Wahlström A; Ståhlman M; Paumgartner G; Marschall HU; Trauner M
    J Hepatol; 2016 Mar; 64(3):674-81. PubMed ID: 26529078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel ASBT inhibitor, IMB17-15, repressed nonalcoholic fatty liver disease development in high-fat diet-fed Syrian golden hamsters.
    Ge MX; Niu WX; Ren JF; Cai SY; Yu DK; Liu HT; Zhang N; Zhang YX; Wang YC; Shao RG; Wang JX; He HW
    Acta Pharmacol Sin; 2019 Jul; 40(7):895-907. PubMed ID: 30573812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast Growth Factor 21 Response in a Preclinical Alcohol Model of Acute-on-Chronic Liver Injury.
    Christidis G; Karatayli E; Hall RA; Weber SN; Reichert MC; Hohl M; Qiao S; Boehm U; Lütjohann D; Lammert F; Karatayli SC
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Inhibiting Ileal Apical versus Basolateral Bile Acid Transport on Cholesterol Metabolism and Atherosclerosis in Mice.
    Dawson PA
    Dig Dis; 2015; 33(3):382-7. PubMed ID: 26045273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of ileal apical but not basolateral bile acid transport reduces atherosclerosis in apoE⁻/⁻ mice.
    Lan T; Haywood J; Dawson PA
    Atherosclerosis; 2013 Aug; 229(2):374-80. PubMed ID: 23880190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kaempferol ameliorated alcoholic liver disease through inhibiting hepatic bile acid synthesis by targeting intestinal FXR-FGF15 signaling.
    Xiao L; Xu G; Chen S; He Y; Peng F; Yuan C
    Phytomedicine; 2023 Nov; 120():155055. PubMed ID: 37678053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atorvastatin induces bile acid-synthetic enzyme Cyp7a1 by suppressing FXR signaling in both liver and intestine in mice.
    Fu ZD; Cui JY; Klaassen CD
    J Lipid Res; 2014 Dec; 55(12):2576-86. PubMed ID: 25278499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic uptake of conjugated bile acids is mediated by both sodium taurocholate cotransporting polypeptide and organic anion transporting polypeptides and modulated by intestinal sensing of plasma bile acid levels in mice.
    Slijepcevic D; Roscam Abbing RLP; Katafuchi T; Blank A; Donkers JM; van Hoppe S; de Waart DR; Tolenaars D; van der Meer JHM; Wildenberg M; Beuers U; Oude Elferink RPJ; Schinkel AH; van de Graaf SFJ
    Hepatology; 2017 Nov; 66(5):1631-1643. PubMed ID: 28498614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial.
    Hegade VS; Kendrick SF; Dobbins RL; Miller SR; Richards D; Storey J; Dukes G; Gilchrist K; Vallow S; Alexander GJ; Corrigan M; Hirschfield GM; Jones DE
    BMC Gastroenterol; 2016 Jul; 16(1):71. PubMed ID: 27431238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of farnesoid X receptor and bile acids in alcoholic liver disease.
    Manley S; Ding W
    Acta Pharm Sin B; 2015 Mar; 5(2):158-67. PubMed ID: 26579442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An FGF15/19-TFEB regulatory loop controls hepatic cholesterol and bile acid homeostasis.
    Wang Y; Gunewardena S; Li F; Matye DJ; Chen C; Chao X; Jung T; Zhang Y; Czerwiński M; Ni HM; Ding WX; Li T
    Nat Commun; 2020 Jul; 11(1):3612. PubMed ID: 32681035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice.
    Rao A; Kosters A; Mells JE; Zhang W; Setchell KD; Amanso AM; Wynn GM; Xu T; Keller BT; Yin H; Banton S; Jones DP; Wu H; Dawson PA; Karpen SJ
    Sci Transl Med; 2016 Sep; 8(357):357ra122. PubMed ID: 27655848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. n-3 Fatty Acids Abrogate Dyslipidemia-Induced Changes in Bile Acid Uptake, Synthesis, and Transport in Young and Aged Dyslipidemic Rats.
    Acharya P; Talahalli RR
    Lipids; 2019 Jan; 54(1):39-51. PubMed ID: 30740707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of ileal bile acid transport and reduced atherosclerosis in apoE-/- mice by SC-435.
    Bhat BG; Rapp SR; Beaudry JA; Napawan N; Butteiger DN; Hall KA; Null CL; Luo Y; Keller BT
    J Lipid Res; 2003 Sep; 44(9):1614-21. PubMed ID: 12810816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice.
    Hartmann P; Hochrath K; Horvath A; Chen P; Seebauer CT; Llorente C; Wang L; Alnouti Y; Fouts DE; Stärkel P; Loomba R; Coulter S; Liddle C; Yu RT; Ling L; Rossi SJ; DePaoli AM; Downes M; Evans RM; Brenner DA; Schnabl B
    Hepatology; 2018 Jun; 67(6):2150-2166. PubMed ID: 29159825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of apical sodium-bile acid transporter inhibitor and obeticholic acid co-treatment in experimental non-alcoholic steatohepatitis.
    Matye DJ; Qin X; Hasan MN; Gu L; Clayton YD; Li F; Li T
    Liver Res; 2022 Dec; 6(4):276-283. PubMed ID: 36819659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FXR Signaling-Mediated Bile Acid Metabolism Is Critical for Alleviation of Cholesterol Gallstones by
    Ye X; Huang D; Dong Z; Wang X; Ning M; Xia J; Shen S; Wu S; Shi Y; Wang J; Wan X
    Microbiol Spectr; 2022 Oct; 10(5):e0051822. PubMed ID: 36036629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.